Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.

Detalles Bibliográficos
Publicado en:Breast Cancer Research Vol. 27; no. 1; pp. 1 - 14
Autores principales: Ravani, Lis Victoria, Bagheri, Zahra, Brufsky, Adam M., Michellon, Isabella, O'Regan, Ruth, Lustberg, Maryam, Han, Hyo, Wang, Ming, Wander, Seth A.
Formato: Journal Article
Publicado: BioMed Central 8/13/2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=187309628&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 187309628
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14655411
        8UYJ
      jtl: Breast Cancer Research
      issn: 14655411
      maglogo: N
    pubinfo:
      dt: 8/13/2025
      vid: 27
      iid: 1
      pid: 24147
      pub: BioMed Central
    artinfo:
      ui:
        187309628
        10.1186/s13058-025-02095-6
        187309628
      ppf: 1
      ppct: 13
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.
      aug:
        au:
          Ravani, Lis Victoria
          Bagheri, Zahra
          Brufsky, Adam M.
          Michellon, Isabella
          O'Regan, Ruth
          Lustberg, Maryam
          Han, Hyo
          Wang, Ming
          Wander, Seth A.
        affil: https://ror.org/036rp1748 Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil
      sug:
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N